Login / Signup

Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE.

Michele L LeNoue-NewtonSheau-Chiann ChenThomas StrickerDavid M HymanNatalie BlauveltPhilippe L BedardFunda Meric-BernstamRinaa S PungliaDeborah SchragEva M LepistoFabrice AndreLillian M SmythSemih DoganCeleste YuChetna WathooMia A LevyLisa D EliFeng XuGrace MannAlshad S LalaniFei YeChristine M MicheelMonica Arnedos
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
ERBB2-activating mutation was not associated with a worse OS from time of first metastatic relapse, or differences in TTP on treatment as compared with a series of matched controls. Although not significant, differences in coexisting mutations (CDH1, ESR1, and KRAS) were noted between the ERBB2-mutated and the control group.
Keyphrases
  • metastatic breast cancer
  • tyrosine kinase
  • wild type
  • squamous cell carcinoma
  • small cell lung cancer
  • signaling pathway
  • quality improvement
  • cross sectional
  • estrogen receptor